Ionis/Akcea's Pfizer-partnered antisense drug shows promise in study, with implications for Arrowhead RNAi asset — analysts
Pfizer forked over $250 million upfront to license an antisense asset from Akcea and its sister company Ionis last year. On Wednesday, the large …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
